Atazanavir
Capsule · trading as Reyataz
To Be Discontinued Active (discontinuing) — Day 344
Moderate impact — Limited manufacturing base (2 known suppliers); substitute sourcing may be constrained.
FDA shortage record
- Substance
- Atazanavir
- Brand name
- Reyataz
- Manufacturers / suppliers
-
- E.R. Squibb & Sons, L.L.C.
- Bristol Myers Squibb Co.
- Dosage form
- Capsule
- Presentation
- Reyataz, Capsule, 300 mg (NDC 0003-3622-12)
- Route(s)
- ORAL
- Therapeutic category
- Antiviral
- Package NDC
0003-3622-12- Initially posted
- 06/04/2025
- Days on shortage list
- 344
- Discontinued
- 06/04/2025
- Current FDA status
- To Be Discontinued
- Shortage entries (current dataset)
- 2 records for Atazanavir
Reason and context
Permanent discontinuation
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 1-800-332-2056; for Medical Inquiries (1-800-321-1335).
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
165cff62-b284-4a27-a65d-9ec8a5bfcdd8). - FDA UNII identifier:
4MT4VIE29P. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.